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Background: The majority of stage III non-small cell lung cancer 
(NSCLC) patients are not candidates for surgery. Five-year survival in 
patients with unresectable NSCLC is less than 10%. Several trials using 
platin-based combination chemotherapy, administred concurrently with 
radiotherapy showed impressive results along with signiﬁcant toxicity. 
We supposed that weekly regimen combined with concomitant radia-
tion would demonstrate lower toxicity. 
Methods: Prospective phase II study. Chemotherapy naive patients 
with newly diagnosed inoperable NSCLC stage IIIA/B, performance 
status 0-1 were involved. Four cycles of low-dose paclitaxel 100 mg/m2 
weekly for 3 of 4 weeks (reduced to 50 mg/m2during radiation therapy) 
combined with four weekly carboplatin AUC 6 were administred, fully 
on outpatient basis. Patients received concomitant normofractionated 
external beam irradiation 65,0-75,0 Gy to primary tumor and regional 
lymph nodes since the second cycle. After the end of treatment patients 
were followed in two months period. In case of tumor recurrence pa-
tients were treated by the second line of chemotherapy.
Results: 24 patients were involved, male/female 23/1, median age 60 
years (range 45-73), stage IIIA 6 (25%), stage IIIB 18 (75%). Squa-
mous cell 12 (50%), adenocarcinoma 7 (29%), undifferentiated 5 
(21%). 89 cycles were administred (264 doses of paclitaxel). Median 
number of cycles was 4 (range 1-4). Median number of paclitaxel doses 
was 12 (range 3 - 12). Only 11 paclitaxel doses had to be delayed. Neu-
tropenia grade 3/4 was found in 4 patients (17%), leukopenia grade 3/4 
in 5 patients (21%), anemia grade 3/4 in 2 patients (8%), esophagitis 
grade 3-4 in 6 patients (25%), pneumonitis grade 3/4 in 2 patients (8%), 
loss of weight grade 3/4 in 1 patient (4%). 20 patients ﬁnished the con-
comitant radiation therapy. No toxic death occurred. Partial response 
was found in 17 patients (71%), stable disease in 3 patients (12%) and 
progression in 4 patients (17%). Median progression free survival was 
38 weeks (range 6-117). Median survival was 71 weeks. 13 patients 
(54%) survived one year. Median follow-up was 19 months. 
Conclusions: Weekly low-dose paclitaxel combined with four weekly 
carboplatin chemotherapy concomitantly with radiotherapy is a well 
tolerated and effective treatment with low toxicity. This combined treat-
ment modality is a reasonable option for patiens with locally advanced 
inoperable NSCLC in performance status 0-1.
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Background: Efﬁcacy of carboplatin plus etoposide chemotherapy for 
non-small cell lung cancer are inferior than regimen platinum based 
combine with new agents such as paclitaxel, docetaxel or gemcitabine. 
However, combined chemotherapy with radiotherapy could improve 
the efﬁcacy, but it could increase toxicities. In our record, the most 
patients who have received carboplatin plus etopside had manageable 
toxicities. To improve the efﬁcacy in non-small cell lung cancer some 
patients were treated by combined full dose carboplatin plus etoposide 
chemotherapy with radiotherapy. The goal of this study was to evaluate 
the outcome of combination carboplatin plus etoposide with radiothera-
py for advanced stage non-small cell lung cancer patients. 
Methods: This was a retrospective survey study. The data were col-
lected from medical records among patient with advance stage non-
small cell lung cancer consequtivelly from January 2000 and December 
2005 treated by 3 weekly carboplatin (AUC-5 on day1) plus etoposide 
(100 mg/m2 on day 1-3) and radiotherapy 200 cGy/day, 5 days/weeks 
with total dose 50 to 60 Gy. In concurrent setting, radiotherapy was not 
given on day 1 chemotherapy. Regarding survival, we have called the 
patients family to know the survival. 
Results: During January 2000 to December 2005 we have diagnosed 
1365 lung cancer cases, 945 cases were treated with chemotherapy 
alone, 180 cases with radiotherapy alone and 215 cases have received 
chemo-radiotherapy. In this study, 79 of 82 patients who have received 
combined carboplatin plus etoposide chemotherapy with radiotherapy 
were analyzed retrospectively. Patient characteristics were 56 (70.9%) 
male and 23 (29.1%) female. Cell cancer types were 63 (79.7%) adeno-
carcinoma 13 (16.5%) squamous cell carcinoma and 3 (3.8%) others. 
Combination chemo-radiotherapy were given in setting concurrently 
were 48 (60. %), alternating were 25 (31.7%) or sequentially were 6 
(7.6%). All patients were administered a median of 5 cycles (range, 4 
to 6 cycles) carboplatin plus etoposide chemotherapy and radiotherapy 
dose range 50 - 60 Gy. The overall response rate (ORR) was 78.7%, 
but only 6 of 79 (7.6%) patients had complete response, 56 of 79 
(70.9%) partial response, 15 of 79 (18.9%) stable diseases and 2 of 79 
(2.6%) progressive diseases. The median time to progression (TTP) 
was 9 weeks (range, 6 to 12 weeks). The median overall survival for all 
patients was 29.5 mos (range, 15 to 44 mos) there was 29.5 mos among 
the concurrent arm, 27 mos among the alternating arm, and 21.5 mos 
among the sequential arm. The 1-yr survival rate, 2- yr survival and 
3-yr survival rate were 100 %, 72.6% %, and 12.7%, respectively. The 
most common toxicity was esophagitis and alopecia. However, there 
was no grade 3-4 hematologic toxicity in either arm.
Conclusion: Chemo-radiotherapy especially concurrent chemo-radio-
therapy using carboplatin-etoposide regimen has a better outcome and 
less toxicity for advanced stage non small cell lung cancer. 
